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Abstract. The potential of circulating tumor cells (CTCs) in 
the diagnosis and prognosis of cancer patients has become 
increasingly attractive. However, molecular analysis of CTCs 
is hindered by low sensitivity and a high level of background 
leukocytes in CTC enrichment technologies. We have devel-
oped a novel protocol using a microfluidic device, which 
enriches and retrieves CTCs from blood samples. The prin-
ciple of CTC capturing is that tumor cells are larger and less 
deformable than normal blood cells. To evaluate the potential 
of utilizing Celsee PREP100 in CTC molecular analysis, we 
prepared prostate cancer cell lines PC3 and LNCaP, retrieved 
the captured cells and analyzed them using PCR amplicon 
sequencing. We were able to recover an average of 79% of 
110-1,100 PC3 and 60-1,500 LNCaP cells, and detect the 
p.K139fs*3 deletion of the p53 gene in PC3 cells and p.T877A 
mutation of the androgen receptor gene in LNCaP cells. 
Next, we spiked these two types of cells into normal donor 
blood samples, captured the cells and analyzed them using 
PCR amplicon sequencing. The PC3 and LNCaP cells were 
captured and retrieved with the ratio of captured CTCs to the 
background leukocytes reaching 1:1.5 for PC3 and 1:2.9 for 
LNCaP cells. We further revealed that the p.K139fs*3 deletion 
and p.T877A mutation can be detected in the captured PC3 
and LNCaP cells, respectively. We successfully validated 
this approach using clinical blood samples from patients with 
metastatic prostate cancer. Our results demonstrated a novel 
approach for CTC enrichment and illustrated the potential of 
CTC molecular characterization for diagnosis, prognosis and 
treatment selection of patients with metastatic malignancy.
Introduction
Circulating tumor cells (CTCs) have been identified in the 
blood and bone marrow of patients with breast, prostate and 
colon cancers (1-3) in as low as 1/100 million or 1 billion 
blood cells. Molecular characterization of CTCs may 
provide a greater understanding of the disease metastases, 
identify aggressive tumors and enable therapeutic selection 
and monitoring of the disease for patients undergoing treat-
ment (4,5). A variety of technologies have been developed 
to improve detection and capture of CTCs from peripheral 
blood, which include immune-magnetic bead separation using 
monoclonal antibodies targeting cell-surface antigens for posi-
tive or negative selection, cell sorting using flow cytometry, 
filtration‑based size separation, density gradient centrifuga-
tion, microfluidic devices and fast‑scan imaging (6‑10). For 
example, CellSearch™ was the first CTC technology that 
demonstrated its clinical validity in predicting progression-free 
and overall survival of metastatic cancer patients based on 
CTC enumeration (3-6).
It is of great interest to go beyond cell enumeration and 
further characterize the CTCs by assessing clinically relevant 
molecular markers on or within CTCs to gain insight into the 
mechanisms of metastasis and best treatment modalities for 
patients (1‑3,11,12). For example, significant progress has been 
made in breast cancer, including effective hormonal therapy, 
chemotherapy and targeted therapies against estrogen receptor 
(ER) and HER-2. In prostate cancer, androgen receptor (AR) 
variant 7 has been implicated in predicting response to targeted 
therapies on AR. Established clinical, pathological features 
and biomarker status are routinely used to guide treatment 
options. It has become critically important to determine which 
patients are most likely to benefit from specific therapies. 
Detecting such molecular markers using a minimally-invasive 
blood test for CTCs has great potential in clinical practice to 
guide therapy choice for patients. However, despite advances 
in CTC technologies, the low frequency of CTCs in cancer 
patients and the extensive background leukocytes have limited 
the synergism of biomarkers and CTC technologies (11,12).
We have developed a novel microf luidic device, 
Celsee PREP100 that uses a size and deformability-based 
capturing mechanism of CTCs (13). The microfluidic chip 
has a parallel network of fluidic channels which contain about 
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56,000 capture chambers (13,14). The chip fabrication begins 
with a silicon master device containing micro-features that 
make up a fluidic network (75‑µm deep), leading to individual 
cell trapping chambers (20x25x30 µm) with a pore size of 
10x8 µm. Each chamber ensures smaller blood cells such as 
red blood cells and most of the leukocytes escape while larger 
cancer cells get trapped and isolated in the chamber. The manu-
facturing process uses standard photo-lithography and deep 
reactive ion etching for micro‑fabrication. From the master 
device, a soft elastomeric negative mold is created by pouring 
and curing against the silicon master. The final micro‑substrate 
is created by hot embossing a plastic plate made of cyclic olefin 
polymer (COP) against the elastomeric negative mold. A thin 
plastic laminate containing pressure-sensitive adhesive is then 
laminated against the COP micro‑substrate to create the final 
microfluidic chip. The chip is placed on the Celsee PREP100 
device for CTC capturing.
Since the device captures cells using a label-free mecha-
nism, it provides an improved sensitivity in capturing CTCs and 
an open platform for investigators to use a variety of antibodies 
to identify and characterize CTCs upon capturing (13,14). In 
a previous study, we compared CTC enumeration between 
the Celsee system and the FDA‑cleared CellSearch system 
using blood samples from patients with metastatic prostate 
cancer. CTC counts were significantly higher using the Celsee 
system (14). The captured CTCs could also be retrieved repro-
ducibly using a back‑flow procedure from the microfluidic chip 
for further nucleic acid extraction and molecular analysis. In 
the present study, we report the development of a novel protocol 
for capturing cells using blood sample retrieval and analysis of 
the cells using PCR amplicon sequencing. Using this method, 
we evaluated the potential of applying Celsee PREP100 in 
CTC molecular analysis by analyzing p.K139fs*3 of TP53 
and p.T877A of AR in captured prostate cancer cell lines PC3 
and LNCaP and in captured spiked-in cells in normal donor 
blood. The method was also tested successfully in clinical 
blood samples from 11 patients with metastatic prostate 
cancer successfully. Our results demonstrated the potential of 
utilizing CTCs for diagnosis, prognosis and treatment selec-
tion of patients with metastatic malignancy.
Materials and methods
Materials. Prostate cancer cell lines PC3 and LNCaP were 
purchased from the American Type Culture Collection (ATCC; 
Manassas, VA, USA) and cultured in Dulbecco's modified 
Eagle's medium (DMEM) containing 5% fetal bovine serum 
(FBS) in a humidified incubator supplemented with 5% CO2. 
Upon confluency, cells were digested with 0.5% trypsin and 
passaged at a 1:4 ratio. Some cells were resuspended in culture 
medium, counted and used for experiments. Blood samples 
were obtained from healthy donors. Clinical blood samples 
from patients with metastatic prostate cancer were obtained 
at Henry Ford Health System (Detroit, MI, USA). The present 
study was approved by the Institutional Review Board (IRB) 
of the Henry Ford Health System and written consent was 
obtained from all patients. Following informed consent, blood 
samples from patients were acquired in 10 ml BCT Cell‑Free 
DNA tubes (Streck, La Vista, NE, USA) or EDTA-coated 
Vacutainer® tubes (BD Biosciences, Franklin Lakes, NJ, USA).
Removal of CD45‑positive cells from blood samples and 
CTC enrichment and staining. To test CTC enrichment 
efficiency using the Celsee PREP100 instrument, 250 PC3 
and 50 LNCaP cells were spiked into 4 ml of blood from 
healthy donors. CD45-positive cells were removed using 
the RosetteSep Human CD45 Depletion Cocktail (Stemcell 
Technologies, Inc., Cambridge, MA, USA) following 
the manufacturer's protocol. The upper layer of plasma 
cells was collected and added into the inlet funnel of the 
Celsee PREP100. Cells were enriched in the microfluidic chip 
and stained for cytokeratins, CD45 and nuclei using anti-Pan 
cytokeratin antibody (1:100 dilution; cat. no. 914204), 
anti‑CD45 antibody (1:100 dilution; cat. no. 368515; both 
antibodies were from BioLegend, Inc., San Diego, CA, USA) 
and DAPI, using Celsee PREP100 CTC Immunochemistry 
kit (Celsee Diagnostics, Plymouth, MI, USA). Cells enriched 
on the slides were counted using the Celsee Analyzer (14). 
Cytokeratins and DAPI-positive and CD45-negative cells 
were counted as CTC cells. The enrichment efficiency was 
calculated as the percentage of the enriched cells of the total 
spiked-in cells.
Cell retrieval using the Celsee PREP100 instrument. A 
different amount of PC3 and LNCaP cells were spiked into 
the priming buffer and retrieved in 2 ml phosphate-buff-
ered saline (PBS) using the Celsee PREP100 instrument 
(Celsee Diagnostics) following the protocol provided by the 
manufacturer. The cells were then concentrated in 10‑50 µl 
by centrifugation at 500 x g for 10 min, and counted using 
a hemocytometer. The retrieval efficiency was calculated as 
the percentage of the retrieved cells of the total spiked-in 
cells.
Retrieval of spiked‑in PC3 and LNCaP cells in normal 
donor blood samples. A different amount of PC3 and LNCaP 
cells were spiked into 4 ml of blood from healthy donors. 
After removal of the CD45-positive cells and enrichment 
of the spiked-in CTCs as aforementioned, cells enriched in 
the microfluidic chip were retrieved in 2 ml PBS using the 
Celsee PREP100 instrument (Celsee Diagnostics) following 
the manufacturer's protocol. These cells were then collected 
by centrifugation at 500 x g for 10 min and stored at ‑20˚C for 
future analysis by PCR amplicon sequencing.
Capturing and retrieval of CTCs in clinical blood samples. 
An aliquot of 4 ml of blood sample was used to capture 
or retrieve CTCs using the Celsee PREP100 instrument 
(Celsee Diagnostics) following the protocol provided by the 
manufacturer. CTCs were monitored using an inverted fluo-
rescence microscope. CTC enumeration following antibody 
labeling was performed manually. PanCK+/CD45- nucleated 
cells were identified as CTCs. Positive and negative controls 
for antibody performance and staining were included in each 
experiment. After removal of CD45-positive cells and enrich-
ment of the spiked-in CTCs as aforementioned, cells enriched 
in the microfluidic chip were retrieved in 2 ml PBS using the 
Celsee PREP100 instrument (Celsee Diagnostics) following 
the manufacturer's protocol. These cells were then collected 
by centrifugation at 500 x g for 10 min and stored at ‑20˚C for 
future analysis by PCR amplicon sequencing.
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PCR amplicon sequencing. Mutations p.K139fs*3 of TP53 
in PC3 and p.T877A of AR in LNCaP cells have been previ-
ously reported (15,16). To detect these mutations, nested PCR 
was employed. Tables I and II lists outer and inner primer 
sets designed to amplify each of the mutations. The retrieved 
cells were resuspended in 5 µl ddH2O and incubated at 4˚C 
for 10 min, and used as the template for PCR amplification. 
The PCR assay was set up in a 20‑µl reaction containing 10 µl 
KAPA HiFi HotStart Ready Mix (Kapa Biosystems, Inc., 
Wilmington, MA, USA), 300 nM of each outer primer and 1 µl 
dimethyl sulfoxide (DMSO) at the following cycling condi-
tions: 2 min at 95˚C, followed in turn by 3 cycles of 20 sec 
at 98˚C, 20 sec at 64˚C and 30 sec at 72˚C, 3 cycles of 20 sec 
at 98˚C, 20 sec at 61˚C and 30 sec at 72˚C, 3 cycles of 20 sec at 
98˚C, 20 sec at 58˚C and 30 sec at 72˚C, 35 cycles of 20 sec at 
98˚C, 20 sec at 57˚C and 30 sec at 72˚C and 10 min at 72˚C. 
One microliter of amplified PCR products with the outer 
primer set was used as the template for the PCR reaction using 
the inner primer set under the same conditions. The final PCR 
products were examined on 1% agarose gel and subjected to 
Sanger sequencing using the inner primers after purification.
Results
Mutation detection in PC3 and LNCaP cell lines. PC3 and 
LNCaP cell lines are established prostate cancer cells and have 
been widely used in studies on prostate cancer. It has been 
reported that PC3 cells possess a deletion in the TP53 gene, 
p.K139fs*3 and LNCaP possess a missense A to G mutation in 
the AR gene, p.T887A mutation (15,16). To detect these muta-
tions, we designed primers (Table I) targeting the mutations, 
performed nested PCR and subsequently sequenced the ampli-
cons by Sanger sequencing. To detect the p.T877A mutation 
of the AR gene in the blood samples of patients, a second 
set of inner primers were used to improve the sensitivity of 
the assay (Table II). Fig. 1 reveals the PCR products and 
Fig. 2 reveals the Sanger sequencing results. The p.K139fs*3 
and p.T887A mutations were successfully detected from 
28-1,200 PC3 cells, and 10-200 LNCaP cells, respectively.
Cell retrieval efficiency using Celsee PREP100. We next 
tested CTC enrichment efficiency of the Celsee PREP100 
by inputting a total of 110, 220, 330, 440, 550, 880 and 1,100 
PC3 cells, and 60, 300, 600, 900, 1,200 and 1,500 LNCaP 
cells, respectively. The results are shown in Table III. Overall, 
the efficiency for cell retrieval was ~70% with a range from 
40 to 121% for PC3 and LNCaP cells. The observation that 
some of the cell recovery rates were >100% was due to the 
variation of cell counts by hemocytometer at low cell numbers.
CTC enrichment and retrieval efficiencies using spiked‑in 
cells in normal donor blood samples. To test the enrich-
ment and retrieval efficiencies of CTC in blood samples, we 
spiked PC3 and LNCaP into 4 ml of whole blood samples 
from healthy donors and stained the enriched cells for cyto-
keratins, CD45 and nuclei. Fig. 3 reveals typical images of 
Table II. Primer sequences used for amplification of fragments 
containing mutations of interest in clinical blood samples.
Mutation p.T877A
Forward outer primer AAAATCAGAGGTTGGGGAAGA
Reverse outer primer ACAACTTGACACTGGGCCATA
Forward inner primer CACCTCCTTGTCAACCCTGT
Reverse inner primer TGGGAAGCAAAGTCTGAAGG
Forward inner primer AGATTGCGAGAGAGCTGCAT
Reverse inner primer TGCCATGGGAGGGTTAGATA
Table I. Primer sequences used for amplification of fragments containing mutations of interest.
Mutation p.K139fs*3 p.T877A
Forward outer primer CTGAGTGACAGAGCAAGACCCTAT AAAATCAGAGGTTGGGGAAGA
Reverse outer primer AGTGTTTCTGTCATCCAAATACTCC ACAACTTGACACTGGGCCATA
Forward inner primer GTTTCTTTGCTGCCGTCTTC CACCTCCTTGTCAACCCTGT
Reverse inner primer ACACGCAAATTTCCTTCCAC TGGGAAGCAAAGTCTGAAGG
Figure 1. Nested PCR amplification of the TP53 gene from PC3 cells and the 
androgen receptor gene from LNCaP cells. (A) Electrophoresis gel imaging 
of nested PCR amplicons from 0, 28, 280, 400, 800 and 1,200 PC3 cells. 
(B) Electrophoresis gel imaging of nested PCR amplicons from 0, 5, 10, 20, 
25, 100 and 200 LNCaP cells.
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Figure 2. Sanger sequencing results of the nested PCR amplicons from PC3 and LNCaP cells. (A) Sequencing results of TP53 from control gDNA (upper panel) 
and PC3 cells (lower panel), revealing a deletion in TP53 from PC3 cells. (B) Sequencing results of AR from control gDNA (upper panel) and LNCaP cells 
(lower panel), revealing a missense mutation in AR from LNCaP cells.
Figure 3. Representative images of the enriched cells using Celsee PREP100. Green, red and blue signals indicate cytokeratins and DAPI‑positive, CD45‑negative 
and nuclei, respectively. (A) Images from individual channels. (B) Composite images from all 3 channels revealing differential staining of CTCs (green) and 
leukocytes (red). It also revealed that circulating tumor cells (CTCs) are captured as a single cell, double cells and cell clusters.
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the enriched cells in the microfluidic chip, where cytokeratins 
and DAPI-positive (green and blue) and CD45-negative cells 
were considered as CTC cells. The results (Table IV) reveals 
that ~40% of 250 spiked‑in PC3 cells and 74% of 50 spiked‑in 
LNCaP cells were retrieved after enrichment. Furthermore, 
the enriched PC3 and LNCaP cells accounted for ~40 and 
25% of the total retrieved cells and the ratio of captured CTCs 
to the background cells reached 1:1.5 for PC3 and 1:2.9 for 
LNCaP cells, suggesting that the removal of blood cells by 
the Celsee PREP100 was nearly complete and the level of 
remaining leukocytes in the enriched sample was very low.
CTC enrichment and retrieval using clinical blood samples. 
To test the enrichment and retrieval efficiencies of CTC the 
blood samples of patients, we stained the enriched cells for 
cytokeratins, CD45 and nuclei. Fig. 3 reveals typical images of 
the enriched cells in the microfluidic chip, where cytokeratins 
and DAPI-positive (green and blue) and CD45-negative cells 
were considered as CTC cells. For the patient samples that had 
CTCs, we processed another 4 ml of the blood samples and 
retrieved CTCs for subsequent mutation analysis.
Mutation analysis. In order to test whether or not the muta-
tions p.K139fs*3 of TP53 in PC3 and p.T877A of AR in 
LNCaP cells could be detected in the enriched cells from 
blood samples, we spiked 50, 100, 300 and 1,000 PC3 cells, 
and 25, 50, 100 and 250 LNCaP cells into 4 ml of blood 
samples, depleted CD45-positive cells, enriched and retrieved 
the cancer cells using Celsee PREP100. The cells were then 
spun down, resuspended in water and used as templates for 
PCR amplification and subsequent Sanger sequencing. Fig. 4 
reveals the PCR products. Fig. 5 shows the Sanger sequencing 
results of the PCR amplicons, indicating that both mutations 
could be successfully detected in the enriched cells. For the 
CTCs retrieved from 14 clinical blood samples, we success-
fully performed the mutation analysis of p.T877A. The AR 
mutation (heterozygous mutation) was identified in the 
1 sample (CTC 37) tested (Fig. 6) and all other samples were 
negative for this mutation. Sixty‑three CTCs were identified in 
sample CTC 37.
Table IV. Efficiency of CTC enrichment from blood samples 
using Celsee PREP100. 
Cell types PC3 LNCaP
No. of spiked-in CTC 250   50
No. of total captured cells  240 146
No. of captured CTC cells    96   37
No. of background cells 144 109
CTC recovery rate (%)   38   74
CTCs vs. background cells (ratio) 1:1.50 1:2.90
CTCs, circulating tumor cells.
Figure 4. PCR products of the TP53 gene from the enriched PC3 cells from 
blood and the androgen receptor gene from enriched LNCaP cells from 
blood. (A) Electrophoresis gel imaging of nested PCR amplicons of the 
enriched cells from blood samples with spiked-in 50, 200, 300, 1,000 PC3 
cells. (B) Electrophoresis of nested PCR amplicons of the enriched cells from 
blood samples with spiked-in 25, 50, 100 and 250 LNCaP cells.
Table III. Efficiency of CTC retrieval using Celsee PREP100. 
Total input PC3 (no. of cells) 110 220 330 440 550 880 1,100
Retrieved PC3 (no. of cells) 128 150 208 531 360 368 750
Recovery rate (%) 116 68 63 121 65 42 68
Total input LNCaP (no. of cells) 60 300 600 900 1,200 1,200 1,500
Retrieved LNCaP (no. of cells) 58 250 618 605 1,233 810 600
Recovery rate (%) 96 83 103 67 103 68 40
CTCs, circulating tumor cells.
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Figure 6. Sanger sequencing results of PCR amplicons of the androgen receptor gene of the enriched patient blood samples. The panel is the representative 
sequencing result of nested PCR amplicons of the patient blood samples (CTC 31 to CTC 41). Sample (CTC 37) carries a heterozygous AR mutation in its 
circulating tumor cells (CTCs). 
Figure 5. Sanger sequencing results of PCR amplicons of the TP53 and androgen receptor genes of the enriched PC3 and LNCaP cells from blood. (A) The 
upper panel is the sequencing result from the control gDNA and the lower panel is the representative sequencing result of nested PCR amplicons of the enriched 
PC3 cells. (B) The representative Sanger sequencing result of nested PCR amplicons of the enriched LNCaP cells. Arrows indicate the mutations.
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Discussion
Molecular characterization of CTCs has been hindered by 
low sensitivity and a high level of background leukocytes 
of currently available CTC enrichment technologies. We 
demonstrated that CTCs can be readily captured and further 
characterized with molecular markers using a simple device, 
Celsee PREP100. The protocol we report in the present 
study enriches and retrieves CTCs from blood samples based 
on the fact that tumor cells are larger and less deformable 
than normal blood cells. To evaluate the performance on 
cell enrichment and retrieval, we prepared prostate cancer 
cell lines PC3 and LNCaP and analyzed the captured cells 
by PCR amplicon sequencing. We were able to recover an 
average of 79% (ranging from 40 to 100%) of 110-1,100 PC3 
cells, and 60-1,500 LNCaP cells and detect the p.K139fs*3 
deletion of TP53 in PC3 cells and the p.T877A mutation 
of AR in LNCaP cells. We also tested these two types of 
cells spiked into normal donor blood samples, captured and 
retrieved the cells and analyzed the retrieved cells by PCR 
amplicon sequencing. We were able to capture ~40% of PC3 
cells and 74% of LNCaP cells with the ratio of captured 
CTCs to the background leukocytes reaching 1:1.5 for PC3 
and 1:2.9 for LNCaP cells. The p.K139fs*3 deletion and the 
p.T877A mutation were detected in the captured spiked-in 
PC3 and LNCaP cells, respectively. The method was also 
tested successfully in clinical blood samples from patients 
with metastatic prostate cancer. Our results demonstrated 
the potential of CTC molecular characterization for the 
diagnosis, prognosis and treatment selection of patients with 
metastatic malignancy.
The unique design of the microf luidic chip and 
Celsee PREP100 allows separation of CTCs from the back-
ground leukocytes and retrieval of the captured CTCs in a 
simple fashion. The variability observed on the recovery rate 
of cell retrieval is mainly due to the nature of the manual 
operation of the protocol. For example, the pressure and speed 
of manual pausing and pumping to retrieve the captured cells 
could vary from experiment to experiment and operator to 
operator. The variable number of background leukocytes could 
come from different healthy donors of the blood samples. To 
improve the purity of captured cells and the consistency of 
the protocol performance, we are developing an automated 
pump that can be connected to the Celsee PREP100 to 
retrieve captured cells from the microfluidic chip for PCR and 
sequencing analyses.
Enrichment of circulating cells can enable a number of 
downstream molecular applications. In addition to Sanger 
sequencing analysis used in our study, RT-PCR and DNA array 
assays on gene expression profiling, as well as NGS analysis on 
several DNA and RNA based genomic applications have been 
explored with enriched CTCs. Fluorescence in situ hybridiza-
tion (FISH) assay on CTCs has also been demonstrated for 
determining gene amplification and aberrant copy number 
changes in cancer cells. Molecular profiling of CTCs could 
produce insightful information towards understanding the 
heterogeneity and the complexity of cancer and shed further 
light on the mechanisms of tumor metastasis, thus delineating 
tumor cells that are relevant to prognosis and therapy choice. 
With improvements on automation and standardization, 
enrichment and characterization of CTCs could overcome the 
technical limitations of low sensitivity and high background 
leukocytes and become a routine diagnostic tool in clinical 
use.
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